ArticleInfectious diseases of poverty2024
Global burden of viral infectious diseases of poverty based on Global Burden of Diseases Study 2021.
Article in Infectious diseases of poverty, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Deep Generative Models for the Discovery of Antiviral Peptides Targeting Dengue Virus: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Global, regional, and national burden of colorectal cancer attributable to modifiable risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.Journal of gastrointestinal oncology · 2026Article
- Recombinant Protein Nanoparticles for Dual-Stage Inhibition of SARS-CoV‑2 Infection.ACS nanoscience Au · 2026Article
- Goat milk-derived bioactive peptides as a health promoter: an insight based on recent in silico studies.Food science of animal resources · 2026Review
- Economic Evaluation of Multi-Objective Schistosomiasis Control Through Systemic Causality: Theoretical Advances and Governance Implications.Tropical medicine and infectious disease · 2026Review
- Status and outlook of mRNA therapeutics for viral diseases.EMBO molecular medicine · 2026Review
- AI-Assisted Differentiation of Dengue and Chikungunya Using Big, Imbalanced Epidemiological Data.Tropical medicine and infectious disease · 2026Article
- Special Issue "Viral Infections: Physiology, Pathophysiology, Pathogenesis, Diagnosis and Treatment".International journal of molecular sciences · 2026Article
- Unveiling the role of extracellular vesicles in HIV infection: molecular mechanisms, viral persistence, and therapeutic opportunities.FEMS microbiology reviews · 2026Review
- Epidemic Comparison of Ebola and Zika-the Only Two Neglected Tropical Diseases with Vertical Transmission Potential and Associated with Public Health Emergency of International Concern-among Childbearing Women.International journal of women's health · 2026Article
- Trends in Incidence and Premature Mortality (Years of Life Lost) From Acute Viral Hepatitis Among Children Under Five in Ethiopia, From 1990 to 2023: A Global Burden of Disease 2023 Study.Global health, epidemiology and genomics · 2026Article
- Global burden and cross-country inequalities in rabies from 1990 to 2021: a systemic analysis of the global burden of disease study 2021.BMC infectious diseases · 2025Article
- Efficacy of Antimicrobials Against Enveloped and Non-Enveloped Viruses on Porous Materials: A Review.Microorganisms · 2025Review
- Global burden of MDR-TB and XDR-TB: trends, inequities, and future implications for public health planning.BMC infectious diseases · 2025Article
- An improved ovitrap-based surveillance framework: facilitating cost-efficient monitoring and efficacy assessment of integrated vector management strategies for dengue outbreak control.Parasites & vectors · 2025Article
- Combating Infectious Diseases in Low-Resource Communities: Socioeconomic, Environmental, Climate Change and Gender-Based Strategies.Journal of preventive medicine and hygiene · 2025Article
- Temporal changes in the burden of type 2 diabetes mellitus across the BRICS, 1990-2021: a comprehensive analysis for the global burden of disease study 2021.BMC public health · 2025Article
- One Health: enabler of effective prevention, control and elimination of emerging and re-emerging infectious diseases.Infectious diseases of poverty · 2025Review
- The global, regional, and national burden trends of dengue among adults aged 20-49 from 1990 to 2021.Scientific reports · 2025Article
- A hybrid framework of generative deep learning for antiviral peptide discovery.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundViral infectious diseases of poverty (vIDPs) remain a significant global health challenge. Despite their profound impact, the burden of these diseases is not comprehensively quantified. This study aims to analyze the global burden of six major vIDPs, including coronavirus disease 2019 (COVID-19), HIV/AIDS, acute hepatitis, dengue, rabies, and Ebola virus disease (EVD), using data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD 2021).
methodsFollowing the GBD 2021 framework, we analyzed the incidence, mortality, and disability-adjusted life years (DALYs) of the six vIDPs across 204 countries and territories from 1990 to 2021. We examined the association between the Socio-Demographic Index (SDI) and the burden of vIDPs. All estimates were reported as numbers and rates per 100,000 population, calculated using the Bayesian statistical model employed by GBD 2021, with 95% uncertainty intervals (UI).
resultsIn 2021, vIDPs caused approximately 8.7 million deaths and 259.2 million DALYs, accounting for 12.8% and 9.0% of the global all-cause totals, respectively. Globally, the burden of vIDPs varied significantly: COVID-19 caused around 7.9 million (95% UI: 7.5, 8.4) deaths and 212.0 million (95% UI 197.9, 234.7) DALYs in 2021. Acute hepatitis had the second-highest age-standardized incidence rate, with 3411.5 (95% UI: 3201.8, 3631.3) per 100,000 population, while HIV/AIDS had a high age-standardized prevalence rate, with 483.1 (95% UI: 459.0, 511.4) per 100,000 population. Dengue incidence cases rose from 26.5 million (95% UI: 3.9, 51.9) in 1990 to 59.0 million (95% UI: 15.5, 106.9) in 2021. Rabies, although reduced in prevalence, continued to pose a significant mortality risk. EVD had the lowest overall burden but significant outbreak impacts. Age-standardized DALY rates for vIDPs were significantly negatively correlated with SDI: acute hepatitis (r = -0.8, P < 0.0001), rabies (r = -0.7, P < 0.0001), HIV/AIDS (r = -0.6, P < 0.0001), COVID-19 (r = -0.5, P < 0.0001), dengue (r = -0.4, P < 0.0001), and EVD (r = -0.2, P < 0.005).
conclusionsVIDPs pose major public health challenges worldwide, with significant regional, age, and gender disparities. The results underscore the need for targeted interventions and international cooperation to mitigate the burden of these diseases. Policymakers can use these findings to implement cost-effective interventions and improve health outcomes, particularly in regions with high or increasing burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.